Benzinga's Top #PreMarket Losers

Avanir Pharmaceuticals (NASDAQ: AVNR ) shares fell 16.32% to $3.59 in the pre-market trading after the company reported that phase II PRIME study of investigation drug AVP-923 did not meet primary efficacy endpoint. The company also reported a wider Q4 loss. Laboratory Corp. of America Holdings (NYSE: LH )